Literature DB >> 3667811

Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography.

R Geschke1, J Körner, H Eggers.   

Abstract

A sensitive high-performance liquid chromatographic method has been developed for the determination of moclobemide and three of its metabolites in plasma and urine. The four substances and the internal standard were extracted from basified plasma (pH 11) with dichloromethane, with recoveries of generally more than 70%. A column packed with 5-microns Spherisorb hexyl phase and an eluent consisting of acetonitrile and aqueous phosphate buffer 30:320 (v/v) with a pH of 3.9 were found most suitable for the chromatographic separation of the four compounds of interest. Non-ideal interactions of the basic compounds and the N-oxide metabolite occurred with many other reversed-phase materials, as indicated by broad and tailing peaks. Limits of quantitation for moclobemide and its three metabolites in the range 20-30 ng/ml and a good intra-assay reproducibility ranging between 2 and 5% for concentrations over 100 ng/ml could be achieved for plasma, which increased to ca. 8-10% at a concentration of 50 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3667811     DOI: 10.1016/0378-4347(87)80160-3

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Gastric decontamination performed 5 min after the ingestion of temazepam, verapamil and moclobemide: charcoal is superior to lavage.

Authors:  O Lapatto-Reiniluoto; K T Kivistö; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines.

Authors:  J Fritze; G Laux; E Sofic; P Koronakis; M P Schoerlin; P Riederer; H Beckmann
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Moclobemide excretion in human breast milk.

Authors:  G Pons; M P Schoerlin; Y K Tam; C Moran; J P Pfefen; C Francoual; A M Pedarriosse; J Chavinie; G Olive
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

4.  Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.

Authors:  Geoffrey K Isbister; L P Hackett; Andrew H Dawson; Ian M Whyte; Anthony J Smith
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

6.  Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.

Authors:  N H Holford; T W Guentert; J Dingemanse; L Banken
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

7.  Determination of Antidepressants and Antipsychotics in Dried Blood Spots (DBSs) Collected from Post-Mortem Samples and Evaluation of the Stability over a Three-Month Period.

Authors:  Matteo Moretti; Francesca Freni; Beatrice Valentini; Claudia Vignali; Angelo Groppi; Silvia Damiana Visonà; Antonio Marco Maria Osculati; Luca Morini
Journal:  Molecules       Date:  2019-10-09       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.